NEOG
Neogen Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -6.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 90.88K | $1.06M | n/a | n/a |
| Q2 2026 | 100 | -3 | 145.70M | $1.31B | +8 | −10 |
| Q1 2026 | 105 | +4 | 149.62M | $1.39B | +10 | −7 |
| Q4 2025 | 101 | +1 | 145.41M | $1.02B | +3 | −1 |
| Q3 2025 | 15 | 0 | 86.70M | $495.04M | +1 | −2 |
| Q2 2025 | 13 | +1 | 84.31M | $402.96M | +2 | −1 |
| Q1 2025 | 9 | 0 | 40.38M | $350.08M | +1 | −1 |
| Q4 2024 | 9 | -2 | 40.94M | $497.00M | n/a | −2 |
| Q3 2024 | 10 | 0 | 36.89M | $620.15M | n/a | n/a |
| Q2 2024 | 10 | n/a | 39.27M | $613.84M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 18.77M | +3.1% | $315.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 11.23M | -3.0% | $188.73M | 0.1% | ▼ Trim | 2 | SEC ↗ ×4 |
| 3 | Geode Capital Management ✦ (passive) | 5.15M | +0.4% | $86.56M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 1.12M | -59.9% | $18.89M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 285.73K | -76.9% | $4.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 124.33K | -6.7% | $2.09M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Marshall Wace ✦ | 65.47K | +249.1% | $1.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 59.73K | +2.6% | $1.00M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 9 | GAMCO Investors ✦ | 56.53K | -19.9% | $950,269 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Bridgewater Associates ✦ | 33.52K | -12.4% | $563,538 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 307 holders, 232.63M shares, $1.97B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · CEO · 505 sh @ 11.95 · $6,035
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology